The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, DENTSPLY Sirona Inc (NASDAQ: XRAY) closed at $13.91 up 0.72% from its previous closing price of $13.81. In other words, the price has increased by $0.72 from its previous closing price. On the day, 2.39 million shares were traded. XRAY stock price reached its highest trading level at $13.935 during the session, while it also had its lowest trading level at $13.715.
Ratios:
For a deeper understanding of DENTSPLY Sirona Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.11. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2774822400 and an Enterprise Value of 4925820416. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76 while its Price-to-Book (P/B) ratio in mrq is 1.41. Its current Enterprise Value per Revenue stands at 1.342 whereas that against EBITDA is 7.869.
Stock Price History:
The Beta on a monthly basis for XRAY is 0.99, which has changed by -0.4453748 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $27.48, while it has fallen to a 52-week low of $12.16. The 50-Day Moving Average of the stock is -7.69%, while the 200-Day Moving Average is calculated to be -15.52%.
Shares Statistics:
For the past three months, XRAY has traded an average of 3.03M shares per day and 2697970 over the past ten days. A total of 199.30M shares are outstanding, with a floating share count of 198.20M. Insiders hold about 0.64% of the company’s shares, while institutions hold 101.87% stake in the company. Shares short for XRAY as of 1755216000 were 7878354 with a Short Ratio of 2.60, compared to 1752537600 on 7839526. Therefore, it implies a Short% of Shares Outstanding of 7878354 and a Short% of Float of 4.4099998000000005.
Dividends & Splits
According to the company, the forward annual dividend rate for XRAY is 0.64, from 0.64 in the trailing year. Against a Trailing Annual Dividend Yield of 0.046343226The stock’s 5-year Average Dividend Yield is 1.75.
Earnings Estimates
The dynamic stock of DENTSPLY Sirona Inc (XRAY) is currently being evaluated by a team of 14.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.44.
Analysts are recommending an EPS of between $1.94 and $1.63 for the fiscal current year, implying an average EPS of $1.87. EPS for the following year is $2.03, with 15.0 analysts recommending between $2.3 and $1.93.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $901.82M this quarter.It ranges from a high estimate of $915.8M to a low estimate of $889M. As of the current estimate, DENTSPLY Sirona Inc’s year-ago sales were $951MFor the next quarter, 14 analysts are estimating revenue of $939.69M. There is a high estimate of $975M for the next quarter, whereas the lowest estimate is $906M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.74B in the next fiscal year. The high estimate is $3.84B and the low estimate is $3.64B.
